FDA Panel Backs Intercept's Liver Disease Drug
April 07, 2016 at 20:42 PM EDT
Its Gastrointestinal Drugs Advisory Committee accepts surrogate endpoint and votes 17-0 to support approval of Intercept's drug for primary biliary cirrhosis.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.